Corrects company name in headline
** Shares of Argenica Therapeutics AGN.AX rise 3.1% to A$0.675, their highest level since Jan. 21
** Clinical drug developer announces that the Data Safety Monitoring Board recommends that trials for its drug ARG-007, continue without any changes
** ARG-007 is a drug to reduce the death of brain tissue after a stroke
** 132,174 shares change hands, 1.4 times the 30-day average
** Stock up 7.9% this month, including session's moves
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。